Kyverna Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	-	-	7.03	5.66
Revenue Growth (YoY)	-	-	-	24.20%	-
Cost of Revenue	127.43	112.47	49.92	28.4	25.85
Gross Profit	-127.43	-112.47	-49.92	-21.38	-20.2
Selling, General & Admin	34.32	30.13	12.48	8.01	6.15
Operating Expenses	34.32	30.13	12.48	8.01	6.15
Operating Income	-161.75	-142.6	-62.41	-29.38	-26.35
Interest Expense	-0.12	-0.14	-0.19	-0.07	-0
Interest & Investment Income	15.45	15.36	2.28	0.57	0
Other Non Operating Income (Expenses)	-0.09	-0.09	-0.06	-0.01	-0
Pretax Income	-145.42	-127.48	-60.37	-28.89	-26.35
Net Income	-145.42	-127.48	-60.37	-28.89	-26.35
Net Income to Common	-145.42	-127.48	-60.37	-28.89	-26.35
Shares Outstanding (Basic)	43	38	1	0	0
Shares Outstanding (Diluted)	43	38	1	0	0
Shares Change (YoY)	6313.09%	5590.81%	47.89%	71.30%	-
EPS (Basic)	-3.37	-3.33	-89.61	-63.43	-99.10
EPS (Diluted)	-3.37	-3.33	-89.61	-63.43	-99.10
Free Cash Flow	-135.3	-116.46	-53.03	-36.88	-23.44
Free Cash Flow Per Share	-3.13	-3.04	-78.72	-80.97	-88.17
Operating Margin	-	-	-	-418.28%	-465.81%
Profit Margin	-	-	-	-411.29%	-465.88%
Free Cash Flow Margin	-	-	-	-525.00%	-414.50%
EBITDA	-160.55	-141.42	-61.54	-28.61	-25.76
D&A For EBITDA	1.2	1.18	0.87	0.78	0.59
EBIT	-161.75	-142.6	-62.41	-29.38	-26.35

Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q